The VANGAS-Trial. The Value of Neurofilament Light Chain & Glial

Status Recruiting

Clinical Trial Summary

Stroke is the second leading cause of death and the third leading cause of disability worldwide. The cause is usually either a blockage or a severe narrowing of a cerebral artery. An important part of stroke prevention is the diagnosis and clarification of stenosis in the arteries supplying the brain, both inside and outside the skull, in order to diagnose a high-grade stenosis at an early stage and offer the patient revascularization. In particular, asymptomatic carotid artery stenosis confronts the diagnosing physician with the question of whether revascularisation is necessary. Risk factors for stroke in asymptomatic carotid artery stenosis include contralateral TIA or cerebral infarction, male gender, rapid progression of the degree of stenosis, plaque morphology, clinically silent cerebral infarctions, Doppler sonographic evidence of microemboli or reduced vasomotor reserve. An established biomarker does not exist at this time. A candidate for such a biomarker in the blood is the protein "neurofilament light chain" (NFL), which is already established in the diagnosis of dementia. As a component of the cytoskeleton of neurons, it is released into the patient's blood when the cells are damaged and can be measured there. Another candidate is glial fibrillary acid protein (GFAP), a part of the cytoskeleton of glial cells that is also released into the blood when glial cells are damaged. A systematic investigation of the value of neurofilament light chain and the glial fibrillary acidic protein in the blood of patients with asymptomatic carotid stenosis is still lacking. VANGAS determines the value of NFL and GFAP from the blood of patients with asymptomatic carotid stenosis to determine associations with the degree of stenosis, the natural course of the stenosis (increase or decrease) and possible symptoms of the stenosis as well as the functional outcome after symptomatic stenosis.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06211725
Study type	Observational
Source	Heinrich-Heine University, Duesseldorf
Contact	Michael / John-Ih / MG Gliem / Lee, MD
Phone	+49174 - 271 57 39
Email	michael.gliem@med.uni-duesseldorf.de
Status	Recruiting
Phase
Start date	January 1, 2023
Completion date	January 1, 2025

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04632485` - Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
Completed	`NCT02133807` - Specific Lp(a) Apheresis for Regression of Coronary and Carotid Atherosclerosis	Phase 3
Completed	`NCT00241787` - Progression of Sub-Clinical Atherosclerosis	N/A
Completed	`NCT00070668` - Inflammatory Genomics in Human Carotid Artery Disease	N/A
Completed	`NCT00035711` - VA HDL Intervention Trial (VA-HIT) Ancillary Study Data Analysis	N/A
Completed	`NCT00005459` - Risk of Coronary Heart Disease in Women With Polycystic Ovary Syndrome	N/A
Completed	`NCT00005479` - Diabetes, Lipoproteins and Accelerated Vascular Disease	N/A
Completed	`NCT00005397` - Epidemiology of Carotid Artery Atherosclerosis in Youth	N/A
Completed	`NCT00005134` - Strong Heart Study	N/A
Completed	`NCT03217214` - Investigation of Contact Based Method for Diagnosis of Cardiovascular Disease
Recruiting	`NCT05455099` - A Multicenter Study of Ultrafast Pulse Wave Velocity in Obese Chinese Han Adults
Recruiting	`NCT06359756` - Ischemic Postconditioning in Carotid Surgery	N/A
Recruiting	`NCT05365490` - Post-approval Study of Transcarotid Artery Revascularization in Standard Risk Patients With Significant Carotid Artery Disease
Recruiting	`NCT04271033` - MicroNet-covered Stent System for Stroke Prevention in All Comer Carotid Revascularization	N/A
Recruiting	`NCT04679727` - The Carotid Artery Multi-modality Imaging Prognostic (CAMP) Study
Recruiting	`NCT05845710` - Direct Access Carotid Artery Stenting Using the Neuroguard IEP System (PERFORMANCE III)	N/A
Recruiting	`NCT05574972` - Timing Carotid Stent Clinical Study for the Treatment of Carotid Artery Stenosis（Timing Trial）	N/A
Recruiting	`NCT05572320` - Platelet Function and Neurological Events
Active, not recruiting	`NCT03351127` - Multicenter Normal Reference Study of Carotid Artery Ultrafast Pulse Wave Velocity (UFPWV)
Completed	`NCT04255316` - Modified Method of Eversion Carotid Endarterectomy in Patients With Extensive Atherosclerotic Disease of Carotid Bifurcation	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

The VANGAS-Trial. The Value of Neurofilament Light Chain and Glial Fibrillary Acid Protein in the Blood of Patients With Asymptomatic Carotid Artery Stenosis — VANGAS

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms